CN104193676A8 - 制备化合物的方法及其合成中间体 - Google Patents

制备化合物的方法及其合成中间体 Download PDF

Info

Publication number
CN104193676A8
CN104193676A8 CN201410380387.8A CN201410380387A CN104193676A8 CN 104193676 A8 CN104193676 A8 CN 104193676A8 CN 201410380387 A CN201410380387 A CN 201410380387A CN 104193676 A8 CN104193676 A8 CN 104193676A8
Authority
CN
China
Prior art keywords
compound
synthetic intermediate
prepare method
present
prepare
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410380387.8A
Other languages
English (en)
Other versions
CN104193676B (zh
CN104193676A (zh
Inventor
S·斯皮纳利
V·利维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eos Ethics Oncology Co "eos Co
Original Assignee
Eos Ethics Oncology Co "eos Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Ethics Oncology Co "eos Co filed Critical Eos Ethics Oncology Co "eos Co
Publication of CN104193676A publication Critical patent/CN104193676A/zh
Application granted granted Critical
Publication of CN104193676B publication Critical patent/CN104193676B/zh
Publication of CN104193676A8 publication Critical patent/CN104193676A8/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/44—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及制备式(I)化合物6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-N-甲基-1-萘甲酰胺的方法及其合成中间体。本发明的方法与以前描述的那些方法相比具有各种优点，尤其是它避免使用酰叠氮中间体及其Curtius重排。
CN201410380387.8A 2009-03-16 2010-03-11 制备化合物的方法及其合成中间体 Expired - Fee Related CN104193676B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2009A000397 2009-03-16
IT2009A000397 2009-03-16
ITMI2009A000397A IT1393351B1 (it) 2009-03-16 2009-03-16 Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
CN201080011948.7A CN102356063B (zh) 2009-03-16 2010-03-11 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080011948.7A Division CN102356063B (zh) 2009-03-16 2010-03-11 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体

Publications (3)

Publication Number Publication Date
CN104193676A CN104193676A (zh) 2014-12-10
CN104193676B CN104193676B (zh) 2016-08-17
CN104193676A8 true CN104193676A8 (zh) 2016-08-17

Family

ID=41210541

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201080011948.7A Expired - Fee Related CN102356063B (zh) 2009-03-16 2010-03-11 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体
CN201410380387.8A Expired - Fee Related CN104193676B (zh) 2009-03-16 2010-03-11 制备化合物的方法及其合成中间体
CN201610565855.8A Pending CN106187882A (zh) 2009-03-16 2010-03-11 制备化合物的方法及其合成中间体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201080011948.7A Expired - Fee Related CN102356063B (zh) 2009-03-16 2010-03-11 制备6-(7-((1-氨基环丙基)甲氧基)-6-甲氧基喹啉-4-基氧基)-n-甲基-1-萘甲酰胺的方法及其合成中间体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610565855.8A Pending CN106187882A (zh) 2009-03-16 2010-03-11 制备化合物的方法及其合成中间体

Country Status (16)

Country Link
US (3) US8642767B2 (zh)
EP (3) EP2408739B1 (zh)
JP (2) JP5817079B2 (zh)
CN (3) CN102356063B (zh)
CY (2) CY1114503T1 (zh)
DK (2) DK2641897T3 (zh)
ES (2) ES2431618T3 (zh)
HK (2) HK1167136A1 (zh)
HR (2) HRP20130978T1 (zh)
HU (1) HUE029528T2 (zh)
IT (1) IT1393351B1 (zh)
PL (2) PL2641897T3 (zh)
PT (2) PT2641897T (zh)
SI (2) SI2641897T1 (zh)
SM (1) SMT201600356B (zh)
WO (1) WO2010105761A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
EA201591205A1 (ru) * 2013-01-18 2015-12-30 Адвенчен Фармасьютикалс, Ллс Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CA2954999C (en) 2014-07-14 2020-01-07 Advenchen Pharmaceuticals, Nanjing Ltd. Fused quinoline compounds as pi3k, mtor inhibitors
EP3231797B1 (en) 2014-12-09 2020-02-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
AU2016293841B2 (en) 2015-07-11 2020-10-08 Advenchen Pharmaceuticals, LLC Fused quinoline compunds as pi3k/mTor inhibitors
CA3000988A1 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
AU2019227391B2 (en) 2018-03-02 2024-06-13 Advenchen Laboratories Nanjing Ltd. Crystal of compound as c-Met kinase inhibitor and preparation method therefor and use thereof
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CN110483392A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体
CN110483393A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 德立替尼的晶型
CN116444489A (zh) * 2018-12-29 2023-07-18 正大天晴药业集团股份有限公司 喹啉衍生物及其制备方法和用途
CN115160221B (zh) * 2022-07-26 2024-10-18 恩祺生物科技(上海)有限公司 德立替尼晶型化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716689B2 (en) * 1996-12-23 2000-03-02 Aventis Pharmaceuticals Inc. 3-aryl-2-(1-substituted-4-piperidinyl)-1(1-DI)oxo-3H-benzo {D}-isothiazole derivatives, their preparation and their use as modulators of neurotransmitter function
MXPA01008182A (es) * 1999-02-10 2003-08-20 Astrazeneca Ab Derivados de quinazolina como inhibidores de angiotensina.
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
EP1699780A1 (en) * 2003-12-23 2006-09-13 Pfizer, Inc. Novel quinoline derivatives
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi

Also Published As

Publication number Publication date
CN106187882A (zh) 2016-12-07
US9340508B2 (en) 2016-05-17
DK2408739T3 (da) 2013-11-04
CY1114503T1 (el) 2016-10-05
JP5817079B2 (ja) 2015-11-18
SI2408739T1 (sl) 2013-11-29
EP3103792A1 (en) 2016-12-14
US20140114075A1 (en) 2014-04-24
WO2010105761A1 (en) 2010-09-23
HK1205105A1 (zh) 2015-12-11
HUE029528T2 (en) 2017-03-28
EP2641897B1 (en) 2016-07-13
EP2408739A1 (en) 2012-01-25
US20120010415A1 (en) 2012-01-12
ITMI20090397A1 (it) 2010-09-17
HK1167136A1 (zh) 2012-11-23
CN104193676B (zh) 2016-08-17
IT1393351B1 (it) 2012-04-20
DK2641897T3 (en) 2016-10-03
PT2408739E (pt) 2013-10-21
PL2408739T3 (pl) 2014-01-31
CY1117871T1 (el) 2017-05-17
CN102356063A (zh) 2012-02-15
HRP20130978T1 (hr) 2013-11-22
JP2015180665A (ja) 2015-10-15
EP2408739B1 (en) 2013-08-14
EP2641897A3 (en) 2013-11-20
US8642767B2 (en) 2014-02-04
HRP20161163T1 (hr) 2016-11-04
JP6061158B2 (ja) 2017-01-18
CN102356063B (zh) 2014-09-24
PL2641897T3 (pl) 2017-01-31
PT2641897T (pt) 2016-08-04
ES2585221T3 (es) 2016-10-04
US9012645B2 (en) 2015-04-21
JP2012520332A (ja) 2012-09-06
SMT201600356B (it) 2016-11-10
EP2641897A2 (en) 2013-09-25
SI2641897T1 (sl) 2016-10-28
CN104193676A (zh) 2014-12-10
US20150191429A1 (en) 2015-07-09
ES2431618T3 (es) 2013-11-27

Similar Documents

Publication Publication Date Title
CN104193676A8 (zh) 制备化合物的方法及其合成中间体
EP4398254A3 (en) Compositions and methods for altering second messenger signaling
IL204763A0 (en) 6,7 - or 8 - substituted quinazolinone derivatives and compositions comprising and methods of using the same
IL217278A0 (en) Nucleic acid - lipid particles, compositions comprising the same and uses thereof
IL201158A0 (en) Soild forms of pemetrexed , compositions comprising the same and processes for the preparation thereof
WO2017087916A3 (en) Thermostable glucose biosensors and uses thereof
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
WO2014144295A8 (en) Ceftolozane antibiotic compositions
WO2019147308A3 (en) Rna nanostructures and methods of making and using rna nanostructures
WO2017011769A3 (en) Il-17f-specific capture agents, compositions, and methods of using and making
WO2017173354A3 (en) METABOLICALLY STABILIZED DOUBLE STRANDED mRNA
WO2017087914A3 (en) Urea biosensors and uses thereof
WO2017106683A3 (en) Concatemeric rna molecules, compositions, and methods and uses thereof
CN107406419A8 (zh) Pet显像剂
WO2015164336A3 (en) Biomass extracts and methods thereof
Shimamura et al. The effect on the texture of butter cake with eggshell powder by soybean polysaccharide
Kavarskas Everyone Ought to Greatly Respect all the Peoples in Lithuania
TH38544S1 (th) แหวน
TH38545S1 (th) แหวน
TH37492S1 (th) ถ้วยกาแฟ
TH106594S (th) ถ้วยกาแฟ
TH46166S1 (th) ปลอกสวมถ้วย
PT1761478E (pt) Impureza de atomoxetina isolada, processos para a preparação de impurezas de atomoxetina e sua utilização como padrões de referência
TH46315S1 (th) ถ้วยวุ้น
TH46316S1 (th) ถ้วย

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Milan Italy

Applicant after: CLOVIS ONCOLOGY ITALY S.R.L.

Address before: Milan Italy

Applicant before: EOS ethics oncology company ("EOS Co.)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: EOS ETHICAL ONCOLOGY SCIENCE S. P. A (IN ABBREVIATED FORM EOS SPA) TO: CLOVIS ONCOLOGY ITALY S. P. A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205105

Country of ref document: HK

C14 Grant of patent or utility model
C53 Correction of patent of invention or patent application
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: MI2009A000397 2009.03.16 IT

False: 2009A000397 2009.03.16 IT

Number: 50

Volume: 30

CI03 Correction of invention patent

Correction item: Priority

Correct: MI2009A000397 2009.03.16 IT

False: 2009A000397 2009.03.16 IT

Number: 50

Page: The title page

Volume: 30

ERR Gazette correction
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1205105

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160817

CF01 Termination of patent right due to non-payment of annual fee